Technical Analysis for PLRX - Pliant Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Historical PLRX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| MACD Bullish Centerline Cross | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| 50 DMA Resistance | Bearish | 1.61% | |
| Crossed Above 20 DMA | Bullish | 1.61% | |
| Fell Below 20 DMA | Bearish | 4.13% | |
| MACD Bearish Centerline Cross | Bearish | 4.13% | |
| MACD Bearish Signal Line Cross | Bearish | 4.13% | |
| 50 DMA Resistance | Bearish | 0.84% | |
| 20 DMA Support | Bullish | 0.84% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 50 DMA Resistance | about 17 hours ago | |
| 10 DMA Resistance | about 17 hours ago | |
| Up 2% | about 17 hours ago | |
| Up 1% | about 19 hours ago | |
| 20 DMA Support | about 20 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: ???
Pliant Therapeutics, Inc. Description
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Alcohol Steatohepatitis Hepatitis Hepatology Non Alcoholic Fatty Liver Disease Fibrosis Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Drug Design Orphan Drug Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Fibrosis Liver Fibrosis Muscular Dystrophies Primary Sclerosing Cholangitis Integrin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.63 |
| 52 Week Low | 19.425 |
| Average Volume | 77,503 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 26.83 |
| 20-Day Moving Average | 25.91 |
| 10-Day Moving Average | 26.66 |
| Average True Range | 1.64 |
| ADX | 13.78 |
| +DI | 17.30 |
| -DI | 21.43 |
| Chandelier Exit (Long, 3 ATRs ) | 23.31 |
| Chandelier Exit (Short, 3 ATRs ) | 27.44 |
| Upper Bollinger Band | 28.69 |
| Lower Bollinger Band | 23.14 |
| Percent B (%b) | 0.61 |
| BandWidth | 21.43 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0004 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 28.29 | ||||
| Resistance 3 (R3) | 28.19 | 27.50 | 27.99 | ||
| Resistance 2 (R2) | 27.50 | 27.04 | 27.55 | 27.89 | |
| Resistance 1 (R1) | 27.00 | 26.76 | 27.25 | 27.10 | 27.79 |
| Pivot Point | 26.30 | 26.30 | 26.43 | 26.35 | 26.30 |
| Support 1 (S1) | 25.80 | 25.85 | 26.05 | 25.90 | 25.21 |
| Support 2 (S2) | 25.11 | 25.56 | 25.16 | 25.11 | |
| Support 3 (S3) | 24.61 | 25.11 | 25.01 | ||
| Support 4 (S4) | 24.71 |
